Materiały źródłowe

• #1

  https://www.alliedacademies.org/articles/nursing-care-in-polycythemia-vera-a-review-article-12618.html

  Polycythemia vera (PV) is a chronic myeloproliferative neoplasm, which is characterised with the clonal proliferation of the erythroid, myeloid and megakaryocytic series. […] While 75-100 mg/day aspirin and phlebotomy is implemented on patients in the low risk group (unless there are contraindications) in order to prevent thrombosis, high risk patients, those who are unable to tolerate phlebotomy and those in progressive circumstances are given cyto-reduction treatment. […] The hydroxyurea used in the treatment of the patients in the medium-high risk group is generally well tolerated by patients, but changes in the skin (loss of hair, hyperpigmentation, erythema, atrophy on the skin, changes in the nails, leg ulcerations) and secondary malignancies do emerge depending on the dose. […] The purpose of this article is to assess the symptoms in connection with PV and the treatment and the difficulties which have been experienced, in accordance with the System for the Categorisation of Nursing Diagnoses of the North American Nursing Diagnosis Association (NANDA) and present possible nursing diagnoses and the management of symptoms according to these diagnoses.

• #2 Polycythemia vera | University of Iowa Health Care

  https://uihc.org/health-topics/polycythemia-vera

  Polycythemia Vera (PV) is a disorder that stimulates an overproduction of red blood cells, white blood cells, and platelets. […] The primary goal of treatment is to lower the number of cells in your blood. […] In addition to the treatment recommended by your doctor, there are steps you can take to help reduce or prevent the symptoms of PV: […] It is important that you be alert for any change or increase in symptoms. If this occurs, it may mean that you need additional or different treatments, and you should contact your doctor right away. […] PV requires regular appointments with your doctor. He or she will want to discuss your symptoms and do periodic blood counts to evaluate your response to treatment. […] Polycythemia Vera is a disorder that cannot be cured, but it can be controlled with treatment. Some patients may only need minimal care and observation, while others may require more intensive treatment.

• #3 Polycythemia | Nurse Key

  https://nursekey.com/polycythemia/

  Polycythemia vera is a primary disorder arising from a chromosomal mutation (a single recurrent JAK2 mutation) most often affecting men of Jewish descent, with onset in late midlife. […] Because of increased viscosity and decreased microcirculation, mortality is high if the condition is left untreated. […] Nursing diagnosis: Acute pain related to headache, angina, pruritus, and abdominal and joint discomfort occurring with altered circulation caused by blood hyperviscosity. […] Assess for presence of headache, angina, abdominal pain, and joint pain. […] Use of a pain intensity scale allows more accurate documentation of discomfort and subsequent relief obtained after analgesia has been administered. […] Instruct patient to request analgesic before pain becomes too intense. […] Encourage use of nonpharmacologic pain control, such as relaxation and distraction.

• #4 Polycythemia Vera – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK557660/

  Polycythemia vera is a myeloproliferative disorder associated with a Janus kinase-2 (JAK2) mutation that causes the neoplastic proliferation of the hematopoietic progenitor cells. […] This activity reviews the evaluation and treatment of polycythemia vera and highlights the role of the interprofessional team in improving care for patients with this condition. […] The role of the interprofessional team to achieve correct diagnosis and management to improve outcomes in patients with polycythemia vera is crucial. This interprofessional team is comprised of clinicians, specialists, mid-level practitioners, nurses, and pharmacists, all working collaboratively and exercising open communication to achieve optimal patient results. […] It is, therefore, important to have frequent follow up with a hematologist for close monitoring and treatment to lower these risks. Treatment options include phlebotomy, daily aspirin, and certain medications to suppress the bone marrow.

• #5 What’s Polycythemia Vera? – Straight A Nursing

  https://straightanursingstudent.com/polycythemia-vera/

  In this article, we’ll be talking about polycythemia vera, the most common of the myeloproliferative neoplasms (MPNs). […] Polycythemia vera occurs due to a malignant change in the DNA of a single cell in the bone marrow. […] This overproduction of cells, namely red blood cells, can result in thrombosis. […] It’s important to note that hemorrhage can also occur. […] As for complications, there are many. Splenomegaly is one of the most common and is more likely to occur in men than in women. […] Another notable and serious complication is the “spent” phase, in which the bone marrow is no longer able to produce functioning blood cells. […] Additionally, hyperuricemia can occur due to the large number of RBCs being produced. […] Polycythemia vera is usually seen in adult males older than 60 years, but can occur at any age.

• #6 What’s Polycythemia Vera? – Straight A Nursing

  https://straightanursingstudent.com/polycythemia-vera/

  In this article, we’ll be talking about polycythemia vera, the most common of the myeloproliferative neoplasms (MPNs). […] Polycythemia vera occurs due to a malignant change in the DNA of a single cell in the bone marrow. […] This overproduction of cells, namely red blood cells, can result in thrombosis. […] It’s important to note that hemorrhage can also occur. […] As for complications, there are many. Splenomegaly is one of the most common and is more likely to occur in men than in women. […] Another notable and serious complication is the “spent” phase, in which the bone marrow is no longer able to produce functioning blood cells. […] Additionally, hyperuricemia can occur due to the large number of RBCs being produced. […] Polycythemia vera is usually seen in adult males older than 60 years, but can occur at any age.

• #7 What’s Polycythemia Vera? – Straight A Nursing

  https://straightanursingstudent.com/polycythemia-vera/

  Many times, PV is asymptomatic and many people are not diagnosed until they have a thrombotic event. […] Assessments for a patient with PV will generally be around recognizing thrombotic events. […] When first diagnosing PV, the MD will most likely order a CBC and EPO level. […] It is important to note there is no cure for polycythemia vera. Treatments are aimed at reducing the risk for thrombosis and managing symptoms. […] For asymptomatic patients at low-risk for disease progression, the standard treatment is low-dose aspirin and phlebotomy to keep the hct below 45%. […] For symptomatic patients, the recommendation is for cytoreductive therapy. […] Pharmacologic therapies are aimed at managing symptoms, reducing the risk of thrombosis, and decreasing blood cell production. […] Non-pharmacologic treatments include: Early ambulation and ROM to improve blood flow and help prevent thrombotic events.

• #8 Polycythemia Vera: What It Is, Symptoms & Treatment

  https://my.clevelandclinic.org/health/diseases/17742-polycythemia-vera

  Polycythemia vera is a chronic condition with no cure, but medical care can help you manage symptoms and the risk of complications. […] The most common treatment for PV is to have regular blood withdrawals. Its the same procedure you would have to donate blood. A healthcare technician inserts a needle into a vein in your arm and withdraws a small amount of blood usually a pint, but it may vary depending on your condition. This reduces your overall blood volume and your number of excess blood cells. […] If youre living with polycythemia vera, its important to keep in touch with your healthcare provider so they can keep track of how your condition is progressing. Let them know how youre responding to treatment and if youre experiencing any side effects. You may continue living a long time without severe symptoms.

• #9 Polycythemia vera – Symptoms & causes – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/polycythemia-vera/symptoms-causes/syc-20355850

  Without treatment, polycythemia vera can be life-threatening. But proper medical care can help ease symptoms and complications of this disease. […] Make an appointment with your healthcare professional if you have symptoms of polycythemia vera.

• #10 What’s Polycythemia Vera? – Straight A Nursing

  https://straightanursingstudent.com/polycythemia-vera/

  Many times, PV is asymptomatic and many people are not diagnosed until they have a thrombotic event. […] Assessments for a patient with PV will generally be around recognizing thrombotic events. […] When first diagnosing PV, the MD will most likely order a CBC and EPO level. […] It is important to note there is no cure for polycythemia vera. Treatments are aimed at reducing the risk for thrombosis and managing symptoms. […] For asymptomatic patients at low-risk for disease progression, the standard treatment is low-dose aspirin and phlebotomy to keep the hct below 45%. […] For symptomatic patients, the recommendation is for cytoreductive therapy. […] Pharmacologic therapies are aimed at managing symptoms, reducing the risk of thrombosis, and decreasing blood cell production. […] Non-pharmacologic treatments include: Early ambulation and ROM to improve blood flow and help prevent thrombotic events.

• #11 https://www.lls.org/myeloproliferative-neoplasms/polycythemia-vera/treatment

  https://www.lls.org/myeloproliferative-neoplasms/polycythemia-vera/treatment

  Polycythemia Vera (PV) is a chronic disease: It’s not curable, but it can usually be managed effectively for very long periods. The goal of therapy is to reduce the risk of thrombosis and to ease symptoms by lowering the number of extra blood cells. […] Many treatment options are designed to manage PV by lowering hematocrit levels below 45 percent for men and 42 percent for women. Careful medical supervision and therapy is important to keep the hematocrit concentration at normal levels. […] Treatment may include: Monitoring for new clots or bleeding, Manage cardiovascular risk factors, Low-dose aspirin, Phlebotomy. […] Treatment may include: Monitoring for new clots or bleeding, Manage cardiovascular risk factors, Low-dose aspirin, Phlebotomy, Medication to reduce the number of blood cells (cytoreductive medication).

• #12 Polycythemia Vera – Hematology & Oncology | Cancer Care Center | Edison | Woodbridge | Union

  https://hocofnj.com/hematology/polycythemia-vera/

  Polycythemia vera is a disorder in which too many red blood cells are produced in the bone marrow. […] As a result of the unusual amount of blood cells, the blood becomes thick than it normally should. […] A common symptom of polycythemia vera is body itching, which is often triggered by warm water prompting the red blood cells to release a chemical that makes you itch. […] Because there is an excessive amount of red blood cells, it can cause your blood to thicken and make breathing more difficult. […] Polycythemia Vera can cause a type of arthritis called Gout, which causes joint pain and swelling, especially affecting the big toe. […] There is no current cure for polycythemia vera. Treatment focuses on reducing your risk of complications. […] Phlebotomy: Involves drawing blood to remove excess red blood cells.

• #13 Nursing care plan for polycythemia

  https://nursipedia.com/nursing-care-plan-polycythemia/

  Nursing care plans for polycythemia is an important part of patient care and management. Nurses are responsible for identifying the signs and symptoms of polycythemia, formulating a plan of care to address the condition, and providing ongoing monitoring and assessment. […] The nurse should also perform a head-to-toe assessment (eyes, ears, nose, throat, chest, abdomen, back and extremities) to identify any signs of polycythemia, such as coughing, shortness of breath, fatigue, and palpitations. […] Based on the initial assessment, the nurse may develop one or more nursing diagnoses for the patient, such as: Ineffective Coping, related to diagnosis of polycythemia and unknown prognosis. […] The desired outcomes for patients with polycythemia may include: Regulation of red and white blood cell production.

• #14 https://www.lls.org/myeloproliferative-neoplasms/polycythemia-vera/treatment

  https://www.lls.org/myeloproliferative-neoplasms/polycythemia-vera/treatment

  Low-dose aspirin may reduce the risk of blood clots, heart attacks and strokes. Low-dose aspirin helps prevent platelets from sticking together, making it less likely for blood clots to form. […] Most PV patients have their blood drawn regularly to reduce the number of blood cells and decrease blood volume. Phlebotomy is a procedure in which blood is taken from a vein similarly to what is done when donating blood. After phlebotomy, the blood is thinner and less likely to cause sludging (which occurs when red blood cells build up along walls of blood vessels). The immediate effect of phlebotomy is to decrease certain symptoms, such as headaches, itchiness, vision problems, ringing in the ears and dizziness. […] High-risk PV patients may be prescribed cytoreductive drugs to reduce the number of blood cells.

• #15 Making a Differential Diagnosis of Polycythemia Vera

  https://www.onclive.com/view/making-a-differential-diagnosis-of-polycythemia-vera

  Polycythemia vera is diagnosed at a median age of roughly about 60 years. In most patients, it is actually diagnosed in an incidental fashion. Someone goes to their primary care physician or some other physician for a regular blood check and is found to have elevated hemoglobin or hematocrit. However, there is a fraction of patients who do present with disease-related symptoms. Now, these could be headaches, or visual disturbances, or pruritis. Or the more complicated ones, including, for example, thrombotic episodes or bleeding episodes. For example, in a large series of about 1,500 patients who had WHO [World Health Organization]defined polycythemia vera, almost a third of patients presented with palpable spleen, had pruritis, also had vasomotor symptoms like erythromelalgia. And in terms of thrombotic episodes, about 16% had an arterial thrombotic episode at the time or prior to their diagnosis. For venous thrombosis that incidence was 7%, and for major hemorrhagic episodes, it was 4%. But in addition to those symptoms, one should also know that elevated white blood cell count and platelet counts can also be present in polycythemia vera. Something on physical exam that we noticed is a facial platter, which is quite classic, but definitely not entirely specific to polycythemia vera. And erythromelalgia is something that we very well know at this point to be associated with polycythemia vera and essential thrombocytosis. Generally, it correlates with a platelet count of more than 400,000 at diagnosis.

• #16 What’s Polycythemia Vera? – Straight A Nursing

  https://straightanursingstudent.com/polycythemia-vera/

  In this article, we’ll be talking about polycythemia vera, the most common of the myeloproliferative neoplasms (MPNs). […] Polycythemia vera occurs due to a malignant change in the DNA of a single cell in the bone marrow. […] This overproduction of cells, namely red blood cells, can result in thrombosis. […] It’s important to note that hemorrhage can also occur. […] As for complications, there are many. Splenomegaly is one of the most common and is more likely to occur in men than in women. […] Another notable and serious complication is the “spent” phase, in which the bone marrow is no longer able to produce functioning blood cells. […] Additionally, hyperuricemia can occur due to the large number of RBCs being produced. […] Polycythemia vera is usually seen in adult males older than 60 years, but can occur at any age.

• #17 Polycythemia Vera – Hematology & Oncology | Cancer Care Center | Edison | Woodbridge | Union

  https://hocofnj.com/hematology/polycythemia-vera/

  Polycythemia vera is a disorder in which too many red blood cells are produced in the bone marrow. […] As a result of the unusual amount of blood cells, the blood becomes thick than it normally should. […] A common symptom of polycythemia vera is body itching, which is often triggered by warm water prompting the red blood cells to release a chemical that makes you itch. […] Because there is an excessive amount of red blood cells, it can cause your blood to thicken and make breathing more difficult. […] Polycythemia Vera can cause a type of arthritis called Gout, which causes joint pain and swelling, especially affecting the big toe. […] There is no current cure for polycythemia vera. Treatment focuses on reducing your risk of complications. […] Phlebotomy: Involves drawing blood to remove excess red blood cells.

• #18 Polycythemia Vera: What’s the Treatment?

  https://www.webmd.com/cancer/polycythemia-vera-treatments

  Polycythemia vera (PV) causes your bone marrow to make too many red blood cells. You need these cells to carry oxygen around your body, but too many of them can make your blood thicken and form clots. Sometimes blood clots lead to a heart attack or stroke. […] Treatments lower the number of red blood cells and prevent blood clots. They also relieve other symptoms, like headaches and vision problems. With the right treatment, you can stay healthy — and feel better. […] This is the main PV treatment. It removes some of your blood to get rid of extra red blood cells. It also lowers your red blood cell count, so your blood thickness starts to get closer to normal. […] You’ll get this treatment once a week or month until your hematocrit goes down to around 45%. Once your red blood cell level has dropped, you’ll get phlebotomy less often.

• #19 What’s Polycythemia Vera? – Straight A Nursing

  https://straightanursingstudent.com/polycythemia-vera/

  In this article, we’ll be talking about polycythemia vera, the most common of the myeloproliferative neoplasms (MPNs). […] Polycythemia vera occurs due to a malignant change in the DNA of a single cell in the bone marrow. […] This overproduction of cells, namely red blood cells, can result in thrombosis. […] It’s important to note that hemorrhage can also occur. […] As for complications, there are many. Splenomegaly is one of the most common and is more likely to occur in men than in women. […] Another notable and serious complication is the “spent” phase, in which the bone marrow is no longer able to produce functioning blood cells. […] Additionally, hyperuricemia can occur due to the large number of RBCs being produced. […] Polycythemia vera is usually seen in adult males older than 60 years, but can occur at any age.

• #20 Making a Differential Diagnosis of Polycythemia Vera

  https://www.onclive.com/view/making-a-differential-diagnosis-of-polycythemia-vera

  Polycythemia vera is diagnosed at a median age of roughly about 60 years. In most patients, it is actually diagnosed in an incidental fashion. Someone goes to their primary care physician or some other physician for a regular blood check and is found to have elevated hemoglobin or hematocrit. However, there is a fraction of patients who do present with disease-related symptoms. Now, these could be headaches, or visual disturbances, or pruritis. Or the more complicated ones, including, for example, thrombotic episodes or bleeding episodes. For example, in a large series of about 1,500 patients who had WHO [World Health Organization]defined polycythemia vera, almost a third of patients presented with palpable spleen, had pruritis, also had vasomotor symptoms like erythromelalgia. And in terms of thrombotic episodes, about 16% had an arterial thrombotic episode at the time or prior to their diagnosis. For venous thrombosis that incidence was 7%, and for major hemorrhagic episodes, it was 4%. But in addition to those symptoms, one should also know that elevated white blood cell count and platelet counts can also be present in polycythemia vera. Something on physical exam that we noticed is a facial platter, which is quite classic, but definitely not entirely specific to polycythemia vera. And erythromelalgia is something that we very well know at this point to be associated with polycythemia vera and essential thrombocytosis. Generally, it correlates with a platelet count of more than 400,000 at diagnosis.

• #21 What’s Polycythemia Vera? – Straight A Nursing

  https://straightanursingstudent.com/polycythemia-vera/

  In this article, we’ll be talking about polycythemia vera, the most common of the myeloproliferative neoplasms (MPNs). […] Polycythemia vera occurs due to a malignant change in the DNA of a single cell in the bone marrow. […] This overproduction of cells, namely red blood cells, can result in thrombosis. […] It’s important to note that hemorrhage can also occur. […] As for complications, there are many. Splenomegaly is one of the most common and is more likely to occur in men than in women. […] Another notable and serious complication is the “spent” phase, in which the bone marrow is no longer able to produce functioning blood cells. […] Additionally, hyperuricemia can occur due to the large number of RBCs being produced. […] Polycythemia vera is usually seen in adult males older than 60 years, but can occur at any age.

• #22 What’s Polycythemia Vera? – Straight A Nursing

  https://straightanursingstudent.com/polycythemia-vera/

  In this article, we’ll be talking about polycythemia vera, the most common of the myeloproliferative neoplasms (MPNs). […] Polycythemia vera occurs due to a malignant change in the DNA of a single cell in the bone marrow. […] This overproduction of cells, namely red blood cells, can result in thrombosis. […] It’s important to note that hemorrhage can also occur. […] As for complications, there are many. Splenomegaly is one of the most common and is more likely to occur in men than in women. […] Another notable and serious complication is the “spent” phase, in which the bone marrow is no longer able to produce functioning blood cells. […] Additionally, hyperuricemia can occur due to the large number of RBCs being produced. […] Polycythemia vera is usually seen in adult males older than 60 years, but can occur at any age.

• #23 Getting Closer to Disease Modification in Polycythemia Vera – Conquer: the journey informed

  https://conquer-magazine.com/issues/2025/vol-11-no-1-february-2025/getting-closer-to-disease-modification-in-polycythemia-vera

  Polycythemia vera is a chronic, incurable disease of the hematopoietic stem cells, the primary cells that can develop into different types of blood cells and are responsible for the production of blood cells during a humans entire life. […] Most affected patients can live a relatively normal and long life. […] Despite the relatively slow progression of the disease course in most patients, the disease possesses its challenges and risks, including a lifetime risk of developing thrombosis (blood clots); the evolution into myelofibrosis, a chronic type of leukemia; or development into acute leukemia. […] Both blood clots and leukemia are consequences that can shorten life expectancy significantly. […] Notwithstanding the rapid advances in therapeutic development, the identification of patients needing therapy and the definition of relevant treatment goals remain challenging.

• #24 Polycythemia vera – Diagnosis & treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/polycythemia-vera/diagnosis-treatment/drc-20355855

  Your healthcare professional takes a medical history and do a physical exam. […] The most common treatment for polycythemia vera is having blood withdrawn often. This is done using a needle in a vein, called phlebotomy. It’s the same procedure used for donating blood. […] Here are ways to feel better if you have polycythemia vera: […] Gentle exercise, such as walking, can improve blood flow. This helps lower the risk of blood clots. […] Using tobacco can narrow your blood vessels. This raises the risk of heart attack or stroke due to blood clots. […] To reduce itching, bathe in cool water, use a gentle cleanser and pat your skin dry. […] Poor blood flow increases your risk of injury from hot and cold temperatures. […] Poor blood flow can make it hard for sores to heal. Look at your hands and feet often. Tell your healthcare professional about any sores.

• #25 Nursing Assessment of Polycythemia – Pathophysiology

  https://www.naxlex.com/nursing/study-guides/nursing-assessment-of-polycythemia-1697449258

  – The nursing assessment of polycythemia involves obtaining a health history, performing a physical examination, and monitoring the vital signs and laboratory results […] – A health history can elicit information about the onset, duration, and severity of symptoms, as well as the presence of risk factors or comorbidities […] – A physical examination can reveal signs of polycythemia, such as a ruddy complexion, cyanosis, hepatomegaly, splenomegaly, bleeding, or thrombosis […] – Vital signs can indicate hypertension, tachycardia, tachypnea, or hypoxia […] – Laboratory results can confirm the diagnosis of polycythemia and its type, as well as monitor the response to treatment […] – A nurse is caring for a patient with polycythemia vera. […] – A nurse is educating a patient with primary polycythemia on potential complications. Which statement by the nurse is accurate regarding the risks associated with this condition?

• #26 What’s Polycythemia Vera? – Straight A Nursing

  https://straightanursingstudent.com/polycythemia-vera/

  Many times, PV is asymptomatic and many people are not diagnosed until they have a thrombotic event. […] Assessments for a patient with PV will generally be around recognizing thrombotic events. […] When first diagnosing PV, the MD will most likely order a CBC and EPO level. […] It is important to note there is no cure for polycythemia vera. Treatments are aimed at reducing the risk for thrombosis and managing symptoms. […] For asymptomatic patients at low-risk for disease progression, the standard treatment is low-dose aspirin and phlebotomy to keep the hct below 45%. […] For symptomatic patients, the recommendation is for cytoreductive therapy. […] Pharmacologic therapies are aimed at managing symptoms, reducing the risk of thrombosis, and decreasing blood cell production. […] Non-pharmacologic treatments include: Early ambulation and ROM to improve blood flow and help prevent thrombotic events.

• #27 Making a Differential Diagnosis of Polycythemia Vera

  https://www.onclive.com/view/making-a-differential-diagnosis-of-polycythemia-vera

  Now, in terms of the diagnostic approach, or testing for polycythemia vera, the clinicians generally tend to follow and try to meet the parameters, the criteria that are part of the WHO major and minor criteria. What that means is that we want to have a sustained hemoglobin of 16.5 for men or more than 16 for women. The numbers in terms of hematocrit are more than 49% for men or 48% for women. Thats one, in other words, sustained erythrocytosis. But also, erythropoietin level should be below the reference range. Turns out to be the minor criteria. These are usually the first set of labs. In addition, one should check for the JAK2 V617F mutation, or in the rare case that it is not present, the JAK2 exon 12 mutations. These could be done from either peripheral blood or from a bone marrow sample, and typically most next-generation sequencing panels have these. And last but not the least, as part of the diagnostic workup is the very important point about bone marrow biopsy. In a classic polycythemia vera case, they should show hypercellularity with panmyelosis. And also, pleomorphic, meaning different sized mature megakaryocytes. The JAK2 mutations, the classic one is V617F mutation found in about a 95% of polycythemia vera patients, while the exon 12 mutation is found in a very small fraction, maybe about 1% to 2%, or maybe around, depending on the series, slightly more percent of patients. But again, the vast majority have the JAK2 V617F mutation.

• #28 Making a Differential Diagnosis of Polycythemia Vera

  https://www.onclive.com/view/making-a-differential-diagnosis-of-polycythemia-vera

  Now, in terms of the diagnostic approach, or testing for polycythemia vera, the clinicians generally tend to follow and try to meet the parameters, the criteria that are part of the WHO major and minor criteria. What that means is that we want to have a sustained hemoglobin of 16.5 for men or more than 16 for women. The numbers in terms of hematocrit are more than 49% for men or 48% for women. Thats one, in other words, sustained erythrocytosis. But also, erythropoietin level should be below the reference range. Turns out to be the minor criteria. These are usually the first set of labs. In addition, one should check for the JAK2 V617F mutation, or in the rare case that it is not present, the JAK2 exon 12 mutations. These could be done from either peripheral blood or from a bone marrow sample, and typically most next-generation sequencing panels have these. And last but not the least, as part of the diagnostic workup is the very important point about bone marrow biopsy. In a classic polycythemia vera case, they should show hypercellularity with panmyelosis. And also, pleomorphic, meaning different sized mature megakaryocytes. The JAK2 mutations, the classic one is V617F mutation found in about a 95% of polycythemia vera patients, while the exon 12 mutation is found in a very small fraction, maybe about 1% to 2%, or maybe around, depending on the series, slightly more percent of patients. But again, the vast majority have the JAK2 V617F mutation.

• #29 Making a Differential Diagnosis of Polycythemia Vera

  https://www.onclive.com/view/making-a-differential-diagnosis-of-polycythemia-vera

  Now, in terms of the diagnostic approach, or testing for polycythemia vera, the clinicians generally tend to follow and try to meet the parameters, the criteria that are part of the WHO major and minor criteria. What that means is that we want to have a sustained hemoglobin of 16.5 for men or more than 16 for women. The numbers in terms of hematocrit are more than 49% for men or 48% for women. Thats one, in other words, sustained erythrocytosis. But also, erythropoietin level should be below the reference range. Turns out to be the minor criteria. These are usually the first set of labs. In addition, one should check for the JAK2 V617F mutation, or in the rare case that it is not present, the JAK2 exon 12 mutations. These could be done from either peripheral blood or from a bone marrow sample, and typically most next-generation sequencing panels have these. And last but not the least, as part of the diagnostic workup is the very important point about bone marrow biopsy. In a classic polycythemia vera case, they should show hypercellularity with panmyelosis. And also, pleomorphic, meaning different sized mature megakaryocytes. The JAK2 mutations, the classic one is V617F mutation found in about a 95% of polycythemia vera patients, while the exon 12 mutation is found in a very small fraction, maybe about 1% to 2%, or maybe around, depending on the series, slightly more percent of patients. But again, the vast majority have the JAK2 V617F mutation.

• #30 Making a Differential Diagnosis of Polycythemia Vera

  https://www.onclive.com/view/making-a-differential-diagnosis-of-polycythemia-vera

  Now, in terms of the diagnostic approach, or testing for polycythemia vera, the clinicians generally tend to follow and try to meet the parameters, the criteria that are part of the WHO major and minor criteria. What that means is that we want to have a sustained hemoglobin of 16.5 for men or more than 16 for women. The numbers in terms of hematocrit are more than 49% for men or 48% for women. Thats one, in other words, sustained erythrocytosis. But also, erythropoietin level should be below the reference range. Turns out to be the minor criteria. These are usually the first set of labs. In addition, one should check for the JAK2 V617F mutation, or in the rare case that it is not present, the JAK2 exon 12 mutations. These could be done from either peripheral blood or from a bone marrow sample, and typically most next-generation sequencing panels have these. And last but not the least, as part of the diagnostic workup is the very important point about bone marrow biopsy. In a classic polycythemia vera case, they should show hypercellularity with panmyelosis. And also, pleomorphic, meaning different sized mature megakaryocytes. The JAK2 mutations, the classic one is V617F mutation found in about a 95% of polycythemia vera patients, while the exon 12 mutation is found in a very small fraction, maybe about 1% to 2%, or maybe around, depending on the series, slightly more percent of patients. But again, the vast majority have the JAK2 V617F mutation.

• #31 Making a Differential Diagnosis of Polycythemia Vera

  https://www.onclive.com/view/making-a-differential-diagnosis-of-polycythemia-vera

  When defining risk for polycythemia vera, I’m mindful of a couple of different concepts. First, risk as it relates to mortality related to the disease, and second, which is the more common situation, risk of having a vascular event, thrombosis or bleeding. Now, our assessment of risk, I think, has evolved over time. First, the assessment of risk of having thrombosis or bleeding has been primarily, in the past, age over 60 or individuals that have had a prior thrombotic event. Now, we recognize that this is not nearly granular enough. Over time, I think there have been several additional parts to the model. First, other contributing factors, an elevated white blood cell count through multiple different studies has been associated with a higher risk of thrombosis. Second, other contributing factors, cardiovascular risk, other poor areas of fitness, strong family history, and hypercholesterolemia. All of these other factors can also really mingle with those other P-vera [polycythemia vera]related risks in terms of risks of vascular events. Over time, there have been additional prognostic scores developed by colleagues such as Ayalew Tefferi [MD at the Mayo Clinic] that have included age, the degree of leukocytosis, etc, in terms of more of a mortality type assessment. […] An individual may be low risk, but if they have significant disease burden symptoms and don’t tolerate phlebotomies, there still may well be an indication for beginning them on medical therapy.

• #32 Pediatric Polycythemia Vera Treatment & Management: Medical Care, Surgical Care, Consultations

  https://emedicine.medscape.com/article/957470-treatment

  In addition, the JAK2 inhibitor ruxolitinib has been approved for second-line treatment of polycythemia vera in patients who are resistant or intolerant to hydroxyurea. […] Patients who are low risk generally do not require chemotherapeutic cytoreductive therapy. […] As stated above, the authors believe that current recommendations to phlebotomize to a goal hematocrit of below 45% in men and under 42% in women may be inaccurate. […] In pregnant women, interferon is the preferred choice to treat polycythemia vera, as it is safe in pregnancy. […] Patients with symptomatic hyperuricemia (gout, urate kidney stones) receive allopurinol. […] Polycythemia vera is not treated surgically, except in the spent phase, when splenectomy may be performed to relieve symptoms related to mass effect and pancytopenia.

• #33 https://www.lls.org/myeloproliferative-neoplasms/polycythemia-vera/treatment

  https://www.lls.org/myeloproliferative-neoplasms/polycythemia-vera/treatment

  A troublesome symptom that occurs in many PV patients is itchy skin (pruritus). Treatment options include: Bathe less frequently, Bathe or shower in cool water and use a gentle soap, Avoid hot tubs, heated whirlpools and hot showers or baths, Keep skin well moisturized with lotion and try not to scratch it because that can damage the skin, Antihistamines such as diphenhydramine (Benadryl) or doxepin may help itching that does not go away, Light therapy (phototherapy) using a medicine called „psoralen” combined with ultraviolet A (UVA) light, Medications such as gabapentin or pregabalin that block neurotransmitters in the central nervous system from sending signals that trigger itching. […] Treatment decisions are based on the patient’s risk for clotting complications (thrombosis). The two main risk factors for thrombosis are: A previous clot or clots, Age 60 years or older.

• #34 Making a Differential Diagnosis of Polycythemia Vera

  https://www.onclive.com/view/making-a-differential-diagnosis-of-polycythemia-vera

  When defining risk for polycythemia vera, I’m mindful of a couple of different concepts. First, risk as it relates to mortality related to the disease, and second, which is the more common situation, risk of having a vascular event, thrombosis or bleeding. Now, our assessment of risk, I think, has evolved over time. First, the assessment of risk of having thrombosis or bleeding has been primarily, in the past, age over 60 or individuals that have had a prior thrombotic event. Now, we recognize that this is not nearly granular enough. Over time, I think there have been several additional parts to the model. First, other contributing factors, an elevated white blood cell count through multiple different studies has been associated with a higher risk of thrombosis. Second, other contributing factors, cardiovascular risk, other poor areas of fitness, strong family history, and hypercholesterolemia. All of these other factors can also really mingle with those other P-vera [polycythemia vera]related risks in terms of risks of vascular events. Over time, there have been additional prognostic scores developed by colleagues such as Ayalew Tefferi [MD at the Mayo Clinic] that have included age, the degree of leukocytosis, etc, in terms of more of a mortality type assessment. […] An individual may be low risk, but if they have significant disease burden symptoms and don’t tolerate phlebotomies, there still may well be an indication for beginning them on medical therapy.

• #35

  https://www.alliedacademies.org/articles/nursing-care-in-polycythemia-vera-a-review-article-12618.html

  Polycythemia vera (PV) is a chronic myeloproliferative neoplasm, which is characterised with the clonal proliferation of the erythroid, myeloid and megakaryocytic series. […] While 75-100 mg/day aspirin and phlebotomy is implemented on patients in the low risk group (unless there are contraindications) in order to prevent thrombosis, high risk patients, those who are unable to tolerate phlebotomy and those in progressive circumstances are given cyto-reduction treatment. […] The hydroxyurea used in the treatment of the patients in the medium-high risk group is generally well tolerated by patients, but changes in the skin (loss of hair, hyperpigmentation, erythema, atrophy on the skin, changes in the nails, leg ulcerations) and secondary malignancies do emerge depending on the dose. […] The purpose of this article is to assess the symptoms in connection with PV and the treatment and the difficulties which have been experienced, in accordance with the System for the Categorisation of Nursing Diagnoses of the North American Nursing Diagnosis Association (NANDA) and present possible nursing diagnoses and the management of symptoms according to these diagnoses.

• #36 https://www.lls.org/myeloproliferative-neoplasms/polycythemia-vera/treatment

  https://www.lls.org/myeloproliferative-neoplasms/polycythemia-vera/treatment

  Polycythemia Vera (PV) is a chronic disease: It’s not curable, but it can usually be managed effectively for very long periods. The goal of therapy is to reduce the risk of thrombosis and to ease symptoms by lowering the number of extra blood cells. […] Many treatment options are designed to manage PV by lowering hematocrit levels below 45 percent for men and 42 percent for women. Careful medical supervision and therapy is important to keep the hematocrit concentration at normal levels. […] Treatment may include: Monitoring for new clots or bleeding, Manage cardiovascular risk factors, Low-dose aspirin, Phlebotomy. […] Treatment may include: Monitoring for new clots or bleeding, Manage cardiovascular risk factors, Low-dose aspirin, Phlebotomy, Medication to reduce the number of blood cells (cytoreductive medication).

• #37 Polycythemia Vera: Rapid Evidence Review | AAFP

  https://www.aafp.org/pubs/afp/issues/2021/0601/p680.html

  Polycythemia vera is one of three stem-cellderived myeloid malignancies commonly known as myeloproliferative neoplasms. […] First-line treatments, such as low-dose aspirin and goal-directed phlebotomy to a hematocrit level of less than 45% to reduce thrombotic events, improve quality of life and prolong survival. […] All people with polycythemia vera should receive phlebotomy with a goal hematocrit level of less than 45%. […] All people who have polycythemia vera without contraindications should take daily low-dose aspirin (40 to 100 mg). […] Hydroxyurea is considered first-line cytoreductive therapy, if indicated. […] Patients with polycythemia vera should be counseled to stop smoking to reduce the risk of thrombosis. […] The goals of therapy are to improve survival and to improve quality of life by decreasing hematocrit levels, symptom burden, bleeding, and clotting complications.

• #38 What’s Polycythemia Vera? – Straight A Nursing

  https://straightanursingstudent.com/polycythemia-vera/

  Many times, PV is asymptomatic and many people are not diagnosed until they have a thrombotic event. […] Assessments for a patient with PV will generally be around recognizing thrombotic events. […] When first diagnosing PV, the MD will most likely order a CBC and EPO level. […] It is important to note there is no cure for polycythemia vera. Treatments are aimed at reducing the risk for thrombosis and managing symptoms. […] For asymptomatic patients at low-risk for disease progression, the standard treatment is low-dose aspirin and phlebotomy to keep the hct below 45%. […] For symptomatic patients, the recommendation is for cytoreductive therapy. […] Pharmacologic therapies are aimed at managing symptoms, reducing the risk of thrombosis, and decreasing blood cell production. […] Non-pharmacologic treatments include: Early ambulation and ROM to improve blood flow and help prevent thrombotic events.

• #39 Polycythemia Vera

  https://cayugamed.staywellknowledgebase.com/Library/NutritionalSupplements/Minerals/85,P00107

  Polycythemia vera (PV) is a rare chronic blood disorder in which there is an increase in all blood cells, particularly red blood cells. […] There is no cure for polycythemia vera. But correct treatment can help to reduce or delay any problems. Work with your provider to create a treatment plan that fits your needs. […] Treatment may include medicines and phlebotomy, a procedure that removes extra blood from your body. […] Sticking to your treatment plan, exercising, getting enough fluids, and staying away from extreme heat and cold can help prevent or decrease symptoms.

• #40 Polycythemia Vera Diagnosis & Treatment – The Patient Story

  https://thepatientstory.com/mpn/polycythemia-vera/diagnosis/

  The medical team develop treatment plans based on the symptoms and risk level specific to the patient. […] Patients with polycythemia vera are most commonly treated with blood withdrawals, also known as phlebotomy. The procedure is exactly like donating blood; a technician will insert a needle and withdraw small amounts of blood. […] Depending on a patient’s risk for blood clots, a doctor may prescribe a low dose of aspirin daily. Aspirin can help prevent blood platelets from sticking together and reduce symptoms of inflammation that patients with PV sometimes experience. […] Generally, three treatments help reduce itching in patients with polycythemia vera. These treatments include: Antihistamines, Phototherapy, Selective serotonin reuptake inhibitors (SSRIs). […] There are several drugs available that can help reduce red blood cell count. However, typically doctors will only prescribe these drugs if phlebotomy alone does not reduce the number of red blood cells in your body.

• #41 Polycythemia Vera: Rapid Evidence Review | AAFP

  https://www.aafp.org/pubs/afp/issues/2021/0601/p680.html

  Polycythemia vera is one of three stem-cellderived myeloid malignancies commonly known as myeloproliferative neoplasms. […] First-line treatments, such as low-dose aspirin and goal-directed phlebotomy to a hematocrit level of less than 45% to reduce thrombotic events, improve quality of life and prolong survival. […] All people with polycythemia vera should receive phlebotomy with a goal hematocrit level of less than 45%. […] All people who have polycythemia vera without contraindications should take daily low-dose aspirin (40 to 100 mg). […] Hydroxyurea is considered first-line cytoreductive therapy, if indicated. […] Patients with polycythemia vera should be counseled to stop smoking to reduce the risk of thrombosis. […] The goals of therapy are to improve survival and to improve quality of life by decreasing hematocrit levels, symptom burden, bleeding, and clotting complications.

• #42 https://www.lls.org/myeloproliferative-neoplasms/polycythemia-vera/treatment

  https://www.lls.org/myeloproliferative-neoplasms/polycythemia-vera/treatment

  Low-dose aspirin may reduce the risk of blood clots, heart attacks and strokes. Low-dose aspirin helps prevent platelets from sticking together, making it less likely for blood clots to form. […] Most PV patients have their blood drawn regularly to reduce the number of blood cells and decrease blood volume. Phlebotomy is a procedure in which blood is taken from a vein similarly to what is done when donating blood. After phlebotomy, the blood is thinner and less likely to cause sludging (which occurs when red blood cells build up along walls of blood vessels). The immediate effect of phlebotomy is to decrease certain symptoms, such as headaches, itchiness, vision problems, ringing in the ears and dizziness. […] High-risk PV patients may be prescribed cytoreductive drugs to reduce the number of blood cells.

• #43 Polycythemia Vera Diagnosis & Treatment – The Patient Story

  https://thepatientstory.com/mpn/polycythemia-vera/diagnosis/

  The medical team develop treatment plans based on the symptoms and risk level specific to the patient. […] Patients with polycythemia vera are most commonly treated with blood withdrawals, also known as phlebotomy. The procedure is exactly like donating blood; a technician will insert a needle and withdraw small amounts of blood. […] Depending on a patient’s risk for blood clots, a doctor may prescribe a low dose of aspirin daily. Aspirin can help prevent blood platelets from sticking together and reduce symptoms of inflammation that patients with PV sometimes experience. […] Generally, three treatments help reduce itching in patients with polycythemia vera. These treatments include: Antihistamines, Phototherapy, Selective serotonin reuptake inhibitors (SSRIs). […] There are several drugs available that can help reduce red blood cell count. However, typically doctors will only prescribe these drugs if phlebotomy alone does not reduce the number of red blood cells in your body.

• #44 Polycythemia Vera – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK557660/

  Patients under the age of 60 without a history of thrombotic events are considered low risk, and treatment recommendations include phlebotomy: Target hematocrit to less than 45%. […] In high-risk patients, cytoreductive therapy is recommended in addition to phlebotomy and aspirin. […] There is currently no difference in treatment recommendations for patients with underlying PV. […] It is recommended that a hematologist be involved in the care of patients with polycythemia vera (PV).

• #45 Polycythemia Vera: Rapid Evidence Review | AAFP

  https://www.aafp.org/pubs/afp/issues/2021/0601/p680.html

  All patients should receive phlebotomy with a goal hematocrit level of less than 45%. […] All patients should receive daily low-dose aspirin (40 to 100 mg) in the absence of contraindications. […] Hydroxyurea is the first-line agent for cytoreductive therapy in PV. […] A multidisciplinary team, including an obstetrician, maternal-fetal medicine specialist, and hematologist, is recommended. […] All pregnant patients who have PV should receive low-dose aspirin, avoid iron supplementation in the absence of actual depletion, maintain gestational age-appropriate hematocrit levels, and be treated with enoxaparin (Lovenox) for six weeks postpartum if no contraindications occur. […] Follow-up appointments every three to six months are recommended for routine history, physical examination, and complete blood count.

• #46 Polycythemia Vera: What’s the Treatment?

  https://www.webmd.com/cancer/polycythemia-vera-treatments

  After your red blood cell level drops, you’ll take one of these prescription drugs to slow the production of new red blood cells in your bone marrow. […] Hydroxyurea is a cancer drug that slows down the growth of new cells in your body. In PV, it lowers the number of red blood cells and platelets, which are cells that help blood clot. […] Your doctor may also consider other treatments such as anagrelide, busulfan (Myleran), imatinib (Gleevec), and ruxolitinib (Jakafi). These medicines help certain types of blood cells work better, so your blood flow improves and is less thick. […] This treatment slows red blood cell production in bone marrow, which thins your blood and helps it flow more easily. […] In addition to your medical plan, use these self-care tips to help you feel better: Exercise daily. Staying active will help keep your blood flowing and prevent clots. […] Drink a lot of water. Extra fluids will help prevent your blood from getting too thick. […] If your concerns start to worry you or get you down, talk to your doctor, a therapist or counselor, or a support group.

• #47

  https://www.alliedacademies.org/articles/nursing-care-in-polycythemia-vera-a-review-article-12618.html

  Polycythemia vera (PV) is a chronic myeloproliferative neoplasm, which is characterised with the clonal proliferation of the erythroid, myeloid and megakaryocytic series. […] While 75-100 mg/day aspirin and phlebotomy is implemented on patients in the low risk group (unless there are contraindications) in order to prevent thrombosis, high risk patients, those who are unable to tolerate phlebotomy and those in progressive circumstances are given cyto-reduction treatment. […] The hydroxyurea used in the treatment of the patients in the medium-high risk group is generally well tolerated by patients, but changes in the skin (loss of hair, hyperpigmentation, erythema, atrophy on the skin, changes in the nails, leg ulcerations) and secondary malignancies do emerge depending on the dose. […] The purpose of this article is to assess the symptoms in connection with PV and the treatment and the difficulties which have been experienced, in accordance with the System for the Categorisation of Nursing Diagnoses of the North American Nursing Diagnosis Association (NANDA) and present possible nursing diagnoses and the management of symptoms according to these diagnoses.

• #48 Pediatric Polycythemia Vera Treatment & Management: Medical Care, Surgical Care, Consultations

  https://emedicine.medscape.com/article/957470-treatment

  In addition, the JAK2 inhibitor ruxolitinib has been approved for second-line treatment of polycythemia vera in patients who are resistant or intolerant to hydroxyurea. […] Patients who are low risk generally do not require chemotherapeutic cytoreductive therapy. […] As stated above, the authors believe that current recommendations to phlebotomize to a goal hematocrit of below 45% in men and under 42% in women may be inaccurate. […] In pregnant women, interferon is the preferred choice to treat polycythemia vera, as it is safe in pregnancy. […] Patients with symptomatic hyperuricemia (gout, urate kidney stones) receive allopurinol. […] Polycythemia vera is not treated surgically, except in the spent phase, when splenectomy may be performed to relieve symptoms related to mass effect and pancytopenia.

• #49 Treatment for Myeloproliferative Neoplasms (MPN) | Memorial Sloan Kettering Cancer Center

  https://www.mskcc.org/cancer-care/types/leukemias/treatment/treatment-myeloproliferative-neoplasms

  For some people, such as those who have had blood clots, chemotherapy is used instead of phlebotomy to stop the excess production of red blood cells. This may include the drug hydroxyurea (Hydrea). It limits the bone marrows ability to make blood cells. […] Interferon may be used to stimulate the immune system and slow the production of red blood cells. For itchy skin, our doctors may prescribe medication, such as an antihistamine. […] People who have taken hydroxyurea but have had either a poor response or side effects can be treated with ruxolitinib (Jakafi), a drug that targets the JAK2 mutation. […] Clinical trials for people with polycythemia vera using new drugs are currently ongoing.

• #50 What Is Polycythemia Vera? (PV) | Jakafi.com

  https://www.jakafi.com/polycythemia-vera/what-is-pv

  Low-dose aspirin therapy is often the first treatment for patients with PV. It may be combined with phlebotomy. […] Patients with PV who have difficulty tolerating phlebotomy, have splenomegaly (an enlarged spleen), or who have elevated blood counts may be candidates for HU, a chemotherapy medicine that reduces the number of red blood cells (RBCs), white blood cells (WBCs), and platelets. […] Jakafi is the first FDA-approved treatment for adults with PV who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.

• #51 Pediatric Polycythemia Vera Treatment & Management: Medical Care, Surgical Care, Consultations

  https://emedicine.medscape.com/article/957470-treatment

  In addition, the JAK2 inhibitor ruxolitinib has been approved for second-line treatment of polycythemia vera in patients who are resistant or intolerant to hydroxyurea. […] Patients who are low risk generally do not require chemotherapeutic cytoreductive therapy. […] As stated above, the authors believe that current recommendations to phlebotomize to a goal hematocrit of below 45% in men and under 42% in women may be inaccurate. […] In pregnant women, interferon is the preferred choice to treat polycythemia vera, as it is safe in pregnancy. […] Patients with symptomatic hyperuricemia (gout, urate kidney stones) receive allopurinol. […] Polycythemia vera is not treated surgically, except in the spent phase, when splenectomy may be performed to relieve symptoms related to mass effect and pancytopenia.

• #52 https://www.lls.org/myeloproliferative-neoplasms/polycythemia-vera/treatment

  https://www.lls.org/myeloproliferative-neoplasms/polycythemia-vera/treatment

  A troublesome symptom that occurs in many PV patients is itchy skin (pruritus). Treatment options include: Bathe less frequently, Bathe or shower in cool water and use a gentle soap, Avoid hot tubs, heated whirlpools and hot showers or baths, Keep skin well moisturized with lotion and try not to scratch it because that can damage the skin, Antihistamines such as diphenhydramine (Benadryl) or doxepin may help itching that does not go away, Light therapy (phototherapy) using a medicine called „psoralen” combined with ultraviolet A (UVA) light, Medications such as gabapentin or pregabalin that block neurotransmitters in the central nervous system from sending signals that trigger itching. […] Treatment decisions are based on the patient’s risk for clotting complications (thrombosis). The two main risk factors for thrombosis are: A previous clot or clots, Age 60 years or older.

• #53 https://www.lls.org/myeloproliferative-neoplasms/polycythemia-vera/treatment

  https://www.lls.org/myeloproliferative-neoplasms/polycythemia-vera/treatment

  A troublesome symptom that occurs in many PV patients is itchy skin (pruritus). Treatment options include: Bathe less frequently, Bathe or shower in cool water and use a gentle soap, Avoid hot tubs, heated whirlpools and hot showers or baths, Keep skin well moisturized with lotion and try not to scratch it because that can damage the skin, Antihistamines such as diphenhydramine (Benadryl) or doxepin may help itching that does not go away, Light therapy (phototherapy) using a medicine called „psoralen” combined with ultraviolet A (UVA) light, Medications such as gabapentin or pregabalin that block neurotransmitters in the central nervous system from sending signals that trigger itching. […] Treatment decisions are based on the patient’s risk for clotting complications (thrombosis). The two main risk factors for thrombosis are: A previous clot or clots, Age 60 years or older.

• #54 Pediatric Polycythemia Vera Treatment & Management: Medical Care, Surgical Care, Consultations

  https://emedicine.medscape.com/article/957470-treatment

  In addition, the JAK2 inhibitor ruxolitinib has been approved for second-line treatment of polycythemia vera in patients who are resistant or intolerant to hydroxyurea. […] Patients who are low risk generally do not require chemotherapeutic cytoreductive therapy. […] As stated above, the authors believe that current recommendations to phlebotomize to a goal hematocrit of below 45% in men and under 42% in women may be inaccurate. […] In pregnant women, interferon is the preferred choice to treat polycythemia vera, as it is safe in pregnancy. […] Patients with symptomatic hyperuricemia (gout, urate kidney stones) receive allopurinol. […] Polycythemia vera is not treated surgically, except in the spent phase, when splenectomy may be performed to relieve symptoms related to mass effect and pancytopenia.

• #55 https://www.lls.org/myeloproliferative-neoplasms/polycythemia-vera/treatment

  https://www.lls.org/myeloproliferative-neoplasms/polycythemia-vera/treatment

  A troublesome symptom that occurs in many PV patients is itchy skin (pruritus). Treatment options include: Bathe less frequently, Bathe or shower in cool water and use a gentle soap, Avoid hot tubs, heated whirlpools and hot showers or baths, Keep skin well moisturized with lotion and try not to scratch it because that can damage the skin, Antihistamines such as diphenhydramine (Benadryl) or doxepin may help itching that does not go away, Light therapy (phototherapy) using a medicine called „psoralen” combined with ultraviolet A (UVA) light, Medications such as gabapentin or pregabalin that block neurotransmitters in the central nervous system from sending signals that trigger itching. […] Treatment decisions are based on the patient’s risk for clotting complications (thrombosis). The two main risk factors for thrombosis are: A previous clot or clots, Age 60 years or older.

• #56 https://www.lls.org/myeloproliferative-neoplasms/polycythemia-vera/treatment

  https://www.lls.org/myeloproliferative-neoplasms/polycythemia-vera/treatment

  A troublesome symptom that occurs in many PV patients is itchy skin (pruritus). Treatment options include: Bathe less frequently, Bathe or shower in cool water and use a gentle soap, Avoid hot tubs, heated whirlpools and hot showers or baths, Keep skin well moisturized with lotion and try not to scratch it because that can damage the skin, Antihistamines such as diphenhydramine (Benadryl) or doxepin may help itching that does not go away, Light therapy (phototherapy) using a medicine called „psoralen” combined with ultraviolet A (UVA) light, Medications such as gabapentin or pregabalin that block neurotransmitters in the central nervous system from sending signals that trigger itching. […] Treatment decisions are based on the patient’s risk for clotting complications (thrombosis). The two main risk factors for thrombosis are: A previous clot or clots, Age 60 years or older.

• #57 Polycythemia Vera: What’s the Treatment?

  https://www.webmd.com/cancer/polycythemia-vera-treatments

  Polycythemia vera (PV) causes your bone marrow to make too many red blood cells. You need these cells to carry oxygen around your body, but too many of them can make your blood thicken and form clots. Sometimes blood clots lead to a heart attack or stroke. […] Treatments lower the number of red blood cells and prevent blood clots. They also relieve other symptoms, like headaches and vision problems. With the right treatment, you can stay healthy — and feel better. […] This is the main PV treatment. It removes some of your blood to get rid of extra red blood cells. It also lowers your red blood cell count, so your blood thickness starts to get closer to normal. […] You’ll get this treatment once a week or month until your hematocrit goes down to around 45%. Once your red blood cell level has dropped, you’ll get phlebotomy less often.

• #58 Polycythemia Vera: What It Is, Symptoms & Treatment

  https://my.clevelandclinic.org/health/diseases/17742-polycythemia-vera

  Polycythemia vera is a chronic condition with no cure, but medical care can help you manage symptoms and the risk of complications. […] The most common treatment for PV is to have regular blood withdrawals. Its the same procedure you would have to donate blood. A healthcare technician inserts a needle into a vein in your arm and withdraws a small amount of blood usually a pint, but it may vary depending on your condition. This reduces your overall blood volume and your number of excess blood cells. […] If youre living with polycythemia vera, its important to keep in touch with your healthcare provider so they can keep track of how your condition is progressing. Let them know how youre responding to treatment and if youre experiencing any side effects. You may continue living a long time without severe symptoms.

• #59 Polycythemia Vera: What’s the Treatment?

  https://www.webmd.com/cancer/polycythemia-vera-treatments

  Polycythemia vera (PV) causes your bone marrow to make too many red blood cells. You need these cells to carry oxygen around your body, but too many of them can make your blood thicken and form clots. Sometimes blood clots lead to a heart attack or stroke. […] Treatments lower the number of red blood cells and prevent blood clots. They also relieve other symptoms, like headaches and vision problems. With the right treatment, you can stay healthy — and feel better. […] This is the main PV treatment. It removes some of your blood to get rid of extra red blood cells. It also lowers your red blood cell count, so your blood thickness starts to get closer to normal. […] You’ll get this treatment once a week or month until your hematocrit goes down to around 45%. Once your red blood cell level has dropped, you’ll get phlebotomy less often.

• #60 Polycythemia Vera: Rapid Evidence Review | AAFP

  https://www.aafp.org/pubs/afp/issues/2021/0601/p680.html

  Polycythemia vera is one of three stem-cellderived myeloid malignancies commonly known as myeloproliferative neoplasms. […] First-line treatments, such as low-dose aspirin and goal-directed phlebotomy to a hematocrit level of less than 45% to reduce thrombotic events, improve quality of life and prolong survival. […] All people with polycythemia vera should receive phlebotomy with a goal hematocrit level of less than 45%. […] All people who have polycythemia vera without contraindications should take daily low-dose aspirin (40 to 100 mg). […] Hydroxyurea is considered first-line cytoreductive therapy, if indicated. […] Patients with polycythemia vera should be counseled to stop smoking to reduce the risk of thrombosis. […] The goals of therapy are to improve survival and to improve quality of life by decreasing hematocrit levels, symptom burden, bleeding, and clotting complications.

• #61 Polycythemia Vera Management: Addressing the Burden of Symptoms and Phlebotomy Dependence

  https://www.ajmc.com/view/polycythemia-vera-management-addressing-the-burden-of-symptoms-and-phlebotomy-dependence

  This ongoing requirement places constraints on patients autonomy and freedom, as they must structure their lives around regular clinic visits and invasive procedures. […] While these therapies effectively lower red blood cell counts, they have not consistently been shown to alleviate PV-related symptoms or meaningfully improve quality of life. […] Although guideline-based therapy can help to effectively manage hematocrit levels for many patients, treatment discontinuation remains a major challenge. […] While PV management remains focused on reducing the risk of thrombotic events, there is growing recognition of the need to address the persistent decline in quality of life experienced by many patients. […] Emphasis on strategies that minimize or eliminate the need for frequent phlebotomy while avoiding additional adverse effects could represent a meaningful step forward in enhancing patient autonomy and well-being. […] Currently, there are no disease-modifying treatment options for patients with PV.

• #62 Polycythemia Vera: What It Is, Symptoms & Treatment

  https://my.clevelandclinic.org/health/diseases/17742-polycythemia-vera

  In addition to regular testing and treatment, your healthcare provider will likely recommend general lifestyle changes to help prevent blood clots and other complications. For example: Exercise. Even moderate exercise can help improve sluggish circulation. Avoid smoking. Smoking causes your blood vessels to narrow. Avoid low-oxygen environments. High altitudes can reduce oxygen levels in your blood. Keep your blood pressure in check. Maintaining a healthy body weight can help with this. […] The most significant threat from polycythemia vera isnt from cancer itself, but from the risk of blood clots. If youre living with PV, make sure to see your healthcare provider regularly. And dont neglect taking care of yourself in the little ways healthy lifestyle habits that can help maintain your general cardiovascular health, which might turn out to be just as important as any medical treatment for polycythemia vera.

• #63 Self-Care for Polycythemia Vera: Exercise, Skin Care, and More

  https://www.healthline.com/health/polycythemia-vera/polycythemia-vera-self-care-from-head-to-toe

  If you have polycythemia vera (PV), its important to keep regular checkups with your doctor, follow your prescribed treatment plan, and adopt these self-care habits to help manage the disease. […] Get regular exercise to promote good blood flow. […] Avoid tobacco to reduce your risk of blood clots. […] Drink plenty of water or other low-calorie fluids. […] Prevent dry skin by bathing in cool water, patting skin dry, and using lotion. […] Avoid sun damage by wearing sunscreen and protective clothing. […] Wear warm gloves, socks, and shoes in cold weather. […] Check your feet regularly for sores and swelling. […] Consider joining a support group for people with this disease. […] Living with PV can be challenging. Consider joining a support group for people with this disease.

• #64 3.9 Polycythemia – Health Alterations

  https://wtcs.pressbooks.pub/healthalts/chapter/3-9-polycythemia/

  Clients with polycythemia vera may experience a variety of symptoms. […] Nursing diagnoses for clients with polycythemia vera are developed based on the clients assessment data, medical history, and specific needs. […] Common nursing diagnoses for polycythemia vera include the following: Risk for Thrombosis, Impaired Gas Exchange, Activity Intolerance, Readiness for Enhanced Knowledge, Impaired Coping. […] Nursing interventions for clients with polycythemia vera focus on preventing thromboses, ensuring adequate oxygenation, assisting with energy management, promoting hydration, managing medications, and providing health teaching to support the clients well-being. […] Nurses help prevent thrombosis formation by promoting adequate hydration, encouraging mobility, and administering anticoagulation therapy as prescribed.

• #65 Nursing care plan for polycythemia

  https://nursipedia.com/nursing-care-plan-polycythemia/

  Nursing care plans for polycythemia is an important part of patient care and management. Nurses are responsible for identifying the signs and symptoms of polycythemia, formulating a plan of care to address the condition, and providing ongoing monitoring and assessment. […] The nurse should also perform a head-to-toe assessment (eyes, ears, nose, throat, chest, abdomen, back and extremities) to identify any signs of polycythemia, such as coughing, shortness of breath, fatigue, and palpitations. […] Based on the initial assessment, the nurse may develop one or more nursing diagnoses for the patient, such as: Ineffective Coping, related to diagnosis of polycythemia and unknown prognosis. […] The desired outcomes for patients with polycythemia may include: Regulation of red and white blood cell production.

• #66 Nursing Assessment of Polycythemia – Pathophysiology

  https://www.naxlex.com/nursing/study-guides/nursing-assessment-of-polycythemia-1697449258

  – The nursing assessment of polycythemia involves obtaining a health history, performing a physical examination, and monitoring the vital signs and laboratory results […] – A health history can elicit information about the onset, duration, and severity of symptoms, as well as the presence of risk factors or comorbidities […] – A physical examination can reveal signs of polycythemia, such as a ruddy complexion, cyanosis, hepatomegaly, splenomegaly, bleeding, or thrombosis […] – Vital signs can indicate hypertension, tachycardia, tachypnea, or hypoxia […] – Laboratory results can confirm the diagnosis of polycythemia and its type, as well as monitor the response to treatment […] – A nurse is caring for a patient with polycythemia vera. […] – A nurse is educating a patient with primary polycythemia on potential complications. Which statement by the nurse is accurate regarding the risks associated with this condition?

• #67 3.9 Polycythemia – Health Alterations

  https://wtcs.pressbooks.pub/healthalts/chapter/3-9-polycythemia/

  Clients with polycythemia vera may experience a variety of symptoms. […] Nursing diagnoses for clients with polycythemia vera are developed based on the clients assessment data, medical history, and specific needs. […] Common nursing diagnoses for polycythemia vera include the following: Risk for Thrombosis, Impaired Gas Exchange, Activity Intolerance, Readiness for Enhanced Knowledge, Impaired Coping. […] Nursing interventions for clients with polycythemia vera focus on preventing thromboses, ensuring adequate oxygenation, assisting with energy management, promoting hydration, managing medications, and providing health teaching to support the clients well-being. […] Nurses help prevent thrombosis formation by promoting adequate hydration, encouraging mobility, and administering anticoagulation therapy as prescribed.

• #68

  https://www.alliedacademies.org/articles/nursing-care-in-polycythemia-vera-a-review-article-12618.html

  Nurses should obtain the detailed history of PV patients; perform a physical examination to get a diagnosis and collect the info associated with the diagnosis tests. […] The important nursing diagnosis related with PV are altered gas exchange, altered tissue perfusion, fatigue, high risk of injury, high risk of infection, deterioration of comfort (itching), high risk of impaired skin integrity and pain. […] Nurses need to use a patient centred approach in the administration of PV, in order to assess the patients, plan care and achieve the self-management of the disease with the patient, who has been empowered with knowledge.

• #69 3.9 Polycythemia – Health Alterations

  https://wtcs.pressbooks.pub/healthalts/chapter/3-9-polycythemia/

  Clients with polycythemia vera may experience a variety of symptoms. […] Nursing diagnoses for clients with polycythemia vera are developed based on the clients assessment data, medical history, and specific needs. […] Common nursing diagnoses for polycythemia vera include the following: Risk for Thrombosis, Impaired Gas Exchange, Activity Intolerance, Readiness for Enhanced Knowledge, Impaired Coping. […] Nursing interventions for clients with polycythemia vera focus on preventing thromboses, ensuring adequate oxygenation, assisting with energy management, promoting hydration, managing medications, and providing health teaching to support the clients well-being. […] Nurses help prevent thrombosis formation by promoting adequate hydration, encouraging mobility, and administering anticoagulation therapy as prescribed.

• #70 Nursing care plan for polycythemia

  https://nursipedia.com/nursing-care-plan-polycythemia/

  The nurse will work with the patient to develop an individualized plan of care to address his or her needs. […] Interventions may include administering prescribed medications, educating the patient on lifestyle modifications and stress management, and providing referrals to support groups or counseling. […] The nurse will assess the patient’s response to the interventions throughout the course of care. […] Nursing care plans for polycythemia are an important component of patient care and management. Ongoing monitoring and assessment are essential for ensuring that the patient is responding to the interventions.

• #71 What’s Polycythemia Vera? – Straight A Nursing

  https://straightanursingstudent.com/polycythemia-vera/

  Teach the patient how often they should have lab studies conducted. […] Ensure the patient understands how to take their medication. […] Teach the patient to avoid sitting cross-legged to promote venous blood flow and help prevent blood clots. […] Teach patients undergoing splenectomy to stay current on all vaccines due to their higher risk for infection. […] If your patient is having a phlebotomy, teach them to maintain adequate hydration status after the procedure and to change position slowly due to risk for orthostatic hypotension. […] To help with bathing-induced pruritis, teach the patient to avoid the use of harsh soaps and scrubbing the skin.

• #72 16.3 Polycythemia – Medical-Surgical Nursing | OpenStax

  https://openstax.org/books/medical-surgical-nursing/pages/16-3-polycythemia

  Acute management of polycythemia centers around treating the cause, if possible; preventing thrombotic events due to the overproduction of RBCs; and symptom improvement. Dependent on the degree of symptoms, nursing interventions are tailored to the patients presentation (Brennan-Cook, 2020). […] Ultimately, nurses assist patients with symptom control and reduction of thrombotic risk (Lu Chang, 2023). Education is important. For example, the patient might be taught to slowly increase their activity level in alignment with their fatigue. […] Evaluation of nursing care for polycythemia centers around symptom management and tailoring interventions and care plans specifically to address each patients unique needs. It is important to perform regular assessments to evaluate how interventions affect symptom improvement.

• #73 Polycythemia | Nurse Key

  https://nursekey.com/polycythemia/

  Polycythemia vera is a primary disorder arising from a chromosomal mutation (a single recurrent JAK2 mutation) most often affecting men of Jewish descent, with onset in late midlife. […] Because of increased viscosity and decreased microcirculation, mortality is high if the condition is left untreated. […] Nursing diagnosis: Acute pain related to headache, angina, pruritus, and abdominal and joint discomfort occurring with altered circulation caused by blood hyperviscosity. […] Assess for presence of headache, angina, abdominal pain, and joint pain. […] Use of a pain intensity scale allows more accurate documentation of discomfort and subsequent relief obtained after analgesia has been administered. […] Instruct patient to request analgesic before pain becomes too intense. […] Encourage use of nonpharmacologic pain control, such as relaxation and distraction.

• #74 Polycythemia | Nurse Key

  https://nursekey.com/polycythemia/

  Polycythemia vera is a primary disorder arising from a chromosomal mutation (a single recurrent JAK2 mutation) most often affecting men of Jewish descent, with onset in late midlife. […] Because of increased viscosity and decreased microcirculation, mortality is high if the condition is left untreated. […] Nursing diagnosis: Acute pain related to headache, angina, pruritus, and abdominal and joint discomfort occurring with altered circulation caused by blood hyperviscosity. […] Assess for presence of headache, angina, abdominal pain, and joint pain. […] Use of a pain intensity scale allows more accurate documentation of discomfort and subsequent relief obtained after analgesia has been administered. […] Instruct patient to request analgesic before pain becomes too intense. […] Encourage use of nonpharmacologic pain control, such as relaxation and distraction.

• #75 What’s Polycythemia Vera? – Straight A Nursing

  https://straightanursingstudent.com/polycythemia-vera/

  Teach the patient how often they should have lab studies conducted. […] Ensure the patient understands how to take their medication. […] Teach the patient to avoid sitting cross-legged to promote venous blood flow and help prevent blood clots. […] Teach patients undergoing splenectomy to stay current on all vaccines due to their higher risk for infection. […] If your patient is having a phlebotomy, teach them to maintain adequate hydration status after the procedure and to change position slowly due to risk for orthostatic hypotension. […] To help with bathing-induced pruritis, teach the patient to avoid the use of harsh soaps and scrubbing the skin.

• #76 What’s Polycythemia Vera? – Straight A Nursing

  https://straightanursingstudent.com/polycythemia-vera/

  Teach the patient how often they should have lab studies conducted. […] Ensure the patient understands how to take their medication. […] Teach the patient to avoid sitting cross-legged to promote venous blood flow and help prevent blood clots. […] Teach patients undergoing splenectomy to stay current on all vaccines due to their higher risk for infection. […] If your patient is having a phlebotomy, teach them to maintain adequate hydration status after the procedure and to change position slowly due to risk for orthostatic hypotension. […] To help with bathing-induced pruritis, teach the patient to avoid the use of harsh soaps and scrubbing the skin.

• #77 Polycythemia Vera: Symptom Burden, Oncology Nurse Considerations, and Patient Education | Oncology Nursing Society

  https://www.ons.org/publications-research/cjon/24/5/polycythemia-vera-symptom-burden-oncology-nurse-considerations-and

  Polycythemia vera (PV) is a rare progressive myelo-proliferative cancer with significant symptom burden. […] Oncology nurses are well suited to assess for symptom burden and to provide educational interventions that support patients and their families. […] Oncology nurses can assess patients with PV for symptom burden while monitoring for thrombotic and vascular events. […] Oncology nurses can support patients with PV and their families by providing ongoing education.

• #78 Assessment and Management of Patients with Polycythemia Vera – Oncology Nurse Advisor

  https://www.oncologynurseadvisor.com/news/assessment-and-management-of-pts-with-pv/

  Oncology nurses have a key role in monitoring disease status of patients with polycythemia vera (PV), and can provide individualized approaches to help alleviate symptom burden for these patients, according to a review article published in the Clinical Journal of Oncology Nursing. […] Because PV may progress slowly, nurses need to report abnormally elevated hemoglobin, hematocrit, and platelet levels, even if the patient appears asymptomatic, because complications may be avoided with early diagnosis and treatment, noted Jill Brennan-Cook, DNP, who authored the review. […] Dr Brennan-Cook recommended following the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Myeloproliferative Neoplasms to facilitate standardized follow-up for patients with PV. […] Oncology nurses are well suited to assess for symptom burden and provide support with educational interventions to patients [with PV] and their families, concluded Dr Brennan-Cook.

• #79 3.9 Polycythemia – Health Alterations

  https://wtcs.pressbooks.pub/healthalts/chapter/3-9-polycythemia/

  Nurses monitor the clients oxygen saturation levels and respiratory status and administer supplemental oxygen as needed to maintain adequate oxygenation. […] Nurses encourage adequate fluid intake to prevent dehydration, reduce blood viscosity, and maintain perfusion of tissues and organs. […] Nurses educate clients about the disease process and potential complications, such as bleeding and thrombosis. The importance of prescribed, routine phlebotomy is emphasized to reduce blood viscosity and prevent potential complications related to thrombosis.

• #80 3.9 Polycythemia – Health Alterations

  https://wtcs.pressbooks.pub/healthalts/chapter/3-9-polycythemia/

  Nurses monitor the clients oxygen saturation levels and respiratory status and administer supplemental oxygen as needed to maintain adequate oxygenation. […] Nurses encourage adequate fluid intake to prevent dehydration, reduce blood viscosity, and maintain perfusion of tissues and organs. […] Nurses educate clients about the disease process and potential complications, such as bleeding and thrombosis. The importance of prescribed, routine phlebotomy is emphasized to reduce blood viscosity and prevent potential complications related to thrombosis.

• #81 What’s Polycythemia Vera? – Straight A Nursing

  https://straightanursingstudent.com/polycythemia-vera/

  Teach the patient how often they should have lab studies conducted. […] Ensure the patient understands how to take their medication. […] Teach the patient to avoid sitting cross-legged to promote venous blood flow and help prevent blood clots. […] Teach patients undergoing splenectomy to stay current on all vaccines due to their higher risk for infection. […] If your patient is having a phlebotomy, teach them to maintain adequate hydration status after the procedure and to change position slowly due to risk for orthostatic hypotension. […] To help with bathing-induced pruritis, teach the patient to avoid the use of harsh soaps and scrubbing the skin.

• #82 What’s Polycythemia Vera? – Straight A Nursing

  https://straightanursingstudent.com/polycythemia-vera/

  Teach the patient how often they should have lab studies conducted. […] Ensure the patient understands how to take their medication. […] Teach the patient to avoid sitting cross-legged to promote venous blood flow and help prevent blood clots. […] Teach patients undergoing splenectomy to stay current on all vaccines due to their higher risk for infection. […] If your patient is having a phlebotomy, teach them to maintain adequate hydration status after the procedure and to change position slowly due to risk for orthostatic hypotension. […] To help with bathing-induced pruritis, teach the patient to avoid the use of harsh soaps and scrubbing the skin.

• #83 Living with Polycythemia Vera | Hematology-Oncology Associates of CNY

  https://www.hoacny.com/patient-resources/blood-disorders/what-polycythemia-vera/living-polycythemia-vera

  Polycythemia vera (PV) develops very slowly. It may not cause signs or symptoms for years. If you have PV, the sooner it’s diagnosed, the sooner your doctor can begin treating you. With proper treatment, you can prevent or delay complications. […] If you have PV, you’ll need lifelong medical care for the disease. Ask your doctor how often you should schedule followup visits. […] Routine care will allow your doctor to detect any changes with your PV and treat them early, if needed. You may need periodic blood tests to show whether the disease is getting worse. […] Follow your treatment plan and take all of your medicines exactly as your doctor prescribes.

• #84 What’s Polycythemia Vera? – Straight A Nursing

  https://straightanursingstudent.com/polycythemia-vera/

  Teach the patient how often they should have lab studies conducted. […] Ensure the patient understands how to take their medication. […] Teach the patient to avoid sitting cross-legged to promote venous blood flow and help prevent blood clots. […] Teach patients undergoing splenectomy to stay current on all vaccines due to their higher risk for infection. […] If your patient is having a phlebotomy, teach them to maintain adequate hydration status after the procedure and to change position slowly due to risk for orthostatic hypotension. […] To help with bathing-induced pruritis, teach the patient to avoid the use of harsh soaps and scrubbing the skin.

• #85 Self-Care for Polycythemia Vera: Exercise, Skin Care, and More

  https://www.healthline.com/health/polycythemia-vera/polycythemia-vera-self-care-from-head-to-toe

  If you have polycythemia vera (PV), its important to keep regular checkups with your doctor, follow your prescribed treatment plan, and adopt these self-care habits to help manage the disease. […] Get regular exercise to promote good blood flow. […] Avoid tobacco to reduce your risk of blood clots. […] Drink plenty of water or other low-calorie fluids. […] Prevent dry skin by bathing in cool water, patting skin dry, and using lotion. […] Avoid sun damage by wearing sunscreen and protective clothing. […] Wear warm gloves, socks, and shoes in cold weather. […] Check your feet regularly for sores and swelling. […] Consider joining a support group for people with this disease. […] Living with PV can be challenging. Consider joining a support group for people with this disease.

• #86 https://www.lls.org/myeloproliferative-neoplasms/polycythemia-vera/treatment

  https://www.lls.org/myeloproliferative-neoplasms/polycythemia-vera/treatment

  A troublesome symptom that occurs in many PV patients is itchy skin (pruritus). Treatment options include: Bathe less frequently, Bathe or shower in cool water and use a gentle soap, Avoid hot tubs, heated whirlpools and hot showers or baths, Keep skin well moisturized with lotion and try not to scratch it because that can damage the skin, Antihistamines such as diphenhydramine (Benadryl) or doxepin may help itching that does not go away, Light therapy (phototherapy) using a medicine called „psoralen” combined with ultraviolet A (UVA) light, Medications such as gabapentin or pregabalin that block neurotransmitters in the central nervous system from sending signals that trigger itching. […] Treatment decisions are based on the patient’s risk for clotting complications (thrombosis). The two main risk factors for thrombosis are: A previous clot or clots, Age 60 years or older.

• #87 Living with Polycythemia Vera | Hematology-Oncology Associates of CNY

  https://www.hoacny.com/patient-resources/blood-disorders/what-polycythemia-vera/living-polycythemia-vera

  Polycythemia vera (PV) develops very slowly. It may not cause signs or symptoms for years. If you have PV, the sooner it’s diagnosed, the sooner your doctor can begin treating you. With proper treatment, you can prevent or delay complications. […] If you have PV, you’ll need lifelong medical care for the disease. Ask your doctor how often you should schedule followup visits. […] Routine care will allow your doctor to detect any changes with your PV and treat them early, if needed. You may need periodic blood tests to show whether the disease is getting worse. […] Follow your treatment plan and take all of your medicines exactly as your doctor prescribes.

• #88 Polycythemia Vera – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK557660/

  Polycythemia vera is a myeloproliferative disorder associated with a Janus kinase-2 (JAK2) mutation that causes the neoplastic proliferation of the hematopoietic progenitor cells. […] This activity reviews the evaluation and treatment of polycythemia vera and highlights the role of the interprofessional team in improving care for patients with this condition. […] The role of the interprofessional team to achieve correct diagnosis and management to improve outcomes in patients with polycythemia vera is crucial. This interprofessional team is comprised of clinicians, specialists, mid-level practitioners, nurses, and pharmacists, all working collaboratively and exercising open communication to achieve optimal patient results. […] It is, therefore, important to have frequent follow up with a hematologist for close monitoring and treatment to lower these risks. Treatment options include phlebotomy, daily aspirin, and certain medications to suppress the bone marrow.

• #89 Diagnosis and Management of Polycythemia Vera Proceedings from a Multidisciplinary Roundtable – Personalized Medicine in Oncology

  https://www.personalizedmedonc.com/supplements/diagnosis-and-management-of-polycythemia-vera/1392:diagnosis-and-management-of-polycythemia-vera-proceedings-from-a-multidisciplinary-roundtable

  Oncology nurses and nurse navigators play an important role as members of a multidisciplinary healthcare team managing patients with PV. Emily A. Knight, RN, BSN, OCN, summarized her responsibilities as a nurse affiliated with an academic center of excellence focused on MPNs. As the primary point of contact for patients with PV and their families, she coordinates appointments, medication authorizations, and laboratory test results. She also serves as a key resource for patient education about symptoms, the disease process, treatment options, medication dosing and side effects, and treatment adherence. When describing her interactions with patients, Ms Knight highlighted the importance of open dialogue and comprehensive knowledge of the disease: When patients trust you, they are more willing to disclose symptoms or issues that they are having. Because we see a large number of patients with MPN, it is easy for me to triage their needs. Nurses in the community only see a few patients with PV. Education is so important for those nurses; they need to know what to look for and what questions to ask when working with these patients.

• #90 Diagnosis and Management of Polycythemia Vera Proceedings from a Multidisciplinary Roundtable – Personalized Medicine in Oncology

  https://www.personalizedmedonc.com/supplements/diagnosis-and-management-of-polycythemia-vera/1392:diagnosis-and-management-of-polycythemia-vera-proceedings-from-a-multidisciplinary-roundtable

  Oncology nurses and nurse navigators play an important role as members of a multidisciplinary healthcare team managing patients with PV. Emily A. Knight, RN, BSN, OCN, summarized her responsibilities as a nurse affiliated with an academic center of excellence focused on MPNs. As the primary point of contact for patients with PV and their families, she coordinates appointments, medication authorizations, and laboratory test results. She also serves as a key resource for patient education about symptoms, the disease process, treatment options, medication dosing and side effects, and treatment adherence. When describing her interactions with patients, Ms Knight highlighted the importance of open dialogue and comprehensive knowledge of the disease: When patients trust you, they are more willing to disclose symptoms or issues that they are having. Because we see a large number of patients with MPN, it is easy for me to triage their needs. Nurses in the community only see a few patients with PV. Education is so important for those nurses; they need to know what to look for and what questions to ask when working with these patients.

• #91 Diagnosis and Management of Polycythemia Vera Proceedings from a Multidisciplinary Roundtable – Personalized Medicine in Oncology

  https://www.personalizedmedonc.com/supplements/diagnosis-and-management-of-polycythemia-vera/1392:diagnosis-and-management-of-polycythemia-vera-proceedings-from-a-multidisciplinary-roundtable

  Oncology nurses and nurse navigators play an important role as members of a multidisciplinary healthcare team managing patients with PV. Emily A. Knight, RN, BSN, OCN, summarized her responsibilities as a nurse affiliated with an academic center of excellence focused on MPNs. As the primary point of contact for patients with PV and their families, she coordinates appointments, medication authorizations, and laboratory test results. She also serves as a key resource for patient education about symptoms, the disease process, treatment options, medication dosing and side effects, and treatment adherence. When describing her interactions with patients, Ms Knight highlighted the importance of open dialogue and comprehensive knowledge of the disease: When patients trust you, they are more willing to disclose symptoms or issues that they are having. Because we see a large number of patients with MPN, it is easy for me to triage their needs. Nurses in the community only see a few patients with PV. Education is so important for those nurses; they need to know what to look for and what questions to ask when working with these patients.

• #92 Polycythemia Vera QI Resources | MPN Quality Initiatives

  https://www.incytempnqualityinitiatives.com/polycythemia-vera-quality-initiatives-resources

  Quality care in oncology is multi-faceted. It entails taking a more holistic approach to the patient rather than just treating the disease. We strive to provide the best care experience, throughout the patient journey, hopefully leading to improved outcomes. Quality initiatives offer the opportunity to refine the care we already provide our patients while showing us where we can improve. […] Involving the nurse in the QI improved ongoing follow up with these patients, because it provided another professional who was involved in care management. The nurse could contact patients who needed updated labs. The nurse could also alert providers of lab work that demonstrated unmanaged PV or inappropriate treatment response. […] This QI has assisted our practice in creating a more proficient approach to PV management. By utilizing the RN for assistance in lab monitoring, we have directly affected patient outcomes. Now, we have modified our workflow and increased the frequency of lab work to every two weeks for patients who are not at target Hct levels of less than 45.

• #93 Diagnosis and Management of Polycythemia Vera Proceedings from a Multidisciplinary Roundtable – Personalized Medicine in Oncology

  https://www.personalizedmedonc.com/supplements/diagnosis-and-management-of-polycythemia-vera/1392:diagnosis-and-management-of-polycythemia-vera-proceedings-from-a-multidisciplinary-roundtable

  Deborah Christensen, RN, HNB-BC, a nurse navigator, then described her role in steering patients through the healthcare system and addressing barriers to care. The Academy of Oncology Nurse Patient Navigators defines a nurse navigator as a clinically trained individual who is responsible for the identification and removal of barriers to timely and appropriate treatment. Nurse navigators are charged with the proactive, personalized guidance of patients throughout their care journey from diagnosis through survivorship. Ms Christensen emphasized the importance of nurses and nurse navigators in ensuring patient adherence to oral medications, and described her centers approach to patient education. She explained, We have established a 4-week coursean oral therapy support classfor our patients who are taking oral cancer medications. The nurse navigator and our social workers focus on adherence issues. A pharmacist talks about safe handling. Our financial resource advocate and pharmacy liaison also meet with them. Patients tell us that the course has been extra helpful for them; they have so many concerns when starting a new medication.

• #94 Diagnosis and Management of Polycythemia Vera Proceedings from a Multidisciplinary Roundtable – Personalized Medicine in Oncology

  https://www.personalizedmedonc.com/supplements/diagnosis-and-management-of-polycythemia-vera/1392:diagnosis-and-management-of-polycythemia-vera-proceedings-from-a-multidisciplinary-roundtable

  Deborah Christensen, RN, HNB-BC, a nurse navigator, then described her role in steering patients through the healthcare system and addressing barriers to care. The Academy of Oncology Nurse Patient Navigators defines a nurse navigator as a clinically trained individual who is responsible for the identification and removal of barriers to timely and appropriate treatment. Nurse navigators are charged with the proactive, personalized guidance of patients throughout their care journey from diagnosis through survivorship. Ms Christensen emphasized the importance of nurses and nurse navigators in ensuring patient adherence to oral medications, and described her centers approach to patient education. She explained, We have established a 4-week coursean oral therapy support classfor our patients who are taking oral cancer medications. The nurse navigator and our social workers focus on adherence issues. A pharmacist talks about safe handling. Our financial resource advocate and pharmacy liaison also meet with them. Patients tell us that the course has been extra helpful for them; they have so many concerns when starting a new medication.

• #95 Diagnosis and Management of Polycythemia Vera Proceedings from a Multidisciplinary Roundtable – Personalized Medicine in Oncology

  https://www.personalizedmedonc.com/supplements/diagnosis-and-management-of-polycythemia-vera/1392:diagnosis-and-management-of-polycythemia-vera-proceedings-from-a-multidisciplinary-roundtable

  Deborah Christensen, RN, HNB-BC, a nurse navigator, then described her role in steering patients through the healthcare system and addressing barriers to care. The Academy of Oncology Nurse Patient Navigators defines a nurse navigator as a clinically trained individual who is responsible for the identification and removal of barriers to timely and appropriate treatment. Nurse navigators are charged with the proactive, personalized guidance of patients throughout their care journey from diagnosis through survivorship. Ms Christensen emphasized the importance of nurses and nurse navigators in ensuring patient adherence to oral medications, and described her centers approach to patient education. She explained, We have established a 4-week coursean oral therapy support classfor our patients who are taking oral cancer medications. The nurse navigator and our social workers focus on adherence issues. A pharmacist talks about safe handling. Our financial resource advocate and pharmacy liaison also meet with them. Patients tell us that the course has been extra helpful for them; they have so many concerns when starting a new medication.

• #96 Polycythemia Vera QI Resources | MPN Quality Initiatives

  https://www.incytempnqualityinitiatives.com/polycythemia-vera-quality-initiatives-resources

  Quality care in oncology is multi-faceted. It entails taking a more holistic approach to the patient rather than just treating the disease. We strive to provide the best care experience, throughout the patient journey, hopefully leading to improved outcomes. Quality initiatives offer the opportunity to refine the care we already provide our patients while showing us where we can improve. […] Involving the nurse in the QI improved ongoing follow up with these patients, because it provided another professional who was involved in care management. The nurse could contact patients who needed updated labs. The nurse could also alert providers of lab work that demonstrated unmanaged PV or inappropriate treatment response. […] This QI has assisted our practice in creating a more proficient approach to PV management. By utilizing the RN for assistance in lab monitoring, we have directly affected patient outcomes. Now, we have modified our workflow and increased the frequency of lab work to every two weeks for patients who are not at target Hct levels of less than 45.

• #97 Question: Living with / Treatment Polycythemia Vera (PV) – General chat – Blood Cancer UK Online Community Forum

  https://forum.bloodcancer.org.uk/t/question-living-with-treatment-polycythemia-vera-pv/11246

  Hi everyone, I am happy to see that there is a community of people with the same rare condition, as even the GP can seem confused about what it is. […] I am nearly at the haematocrit 0.45 mark (one or two more weeks) and I’ve been told to go to an every 14 day venesection. […] I also had weekly phlebotomy after diagnosis last year to bring my haematocrit down to 45 %, and then monthly once it stabilised, and actually now it’s about every 3 months, as needed. […] Our haematologists also base our treatments on how high risk we are classed, which I believe is whether we’ve had a clotting event prior to diagnosis and whether we’re classed as young (which seems to be younger than 60). […] I started on hydroxyurea and it seems to suit me well after a year, although it has made my skin dry out and photosensitive.

• #98 Polycythemia Vera: What It Is, Symptoms & Treatment

  https://my.clevelandclinic.org/health/diseases/17742-polycythemia-vera

  Polycythemia vera is a chronic condition with no cure, but medical care can help you manage symptoms and the risk of complications. […] The most common treatment for PV is to have regular blood withdrawals. Its the same procedure you would have to donate blood. A healthcare technician inserts a needle into a vein in your arm and withdraws a small amount of blood usually a pint, but it may vary depending on your condition. This reduces your overall blood volume and your number of excess blood cells. […] If youre living with polycythemia vera, its important to keep in touch with your healthcare provider so they can keep track of how your condition is progressing. Let them know how youre responding to treatment and if youre experiencing any side effects. You may continue living a long time without severe symptoms.

• #99 Self-Care for Polycythemia Vera: Exercise, Skin Care, and More

  https://www.healthline.com/health/polycythemia-vera/polycythemia-vera-self-care-from-head-to-toe

  When living with PV, avoid bathing in hot water, such as in hot tubs or showers. Your doctor is also likely to ask you to avoid or stop smoking. […] When you have PV, staying hydrated is important. It will help you keep good blood flow and circulation, as well as prevent dehydration. […] The treatment for PV is usually low dose aspirin, phlebotomy, and in some cases, drugs that help reduce the number of blood cells. You’ll also be monitored for new blood clots, and you may have to make some lifestyle changes to reduce your risk of heart problems. […] Treatment is available, and adjusting some lifestyle habits like staying active, staying hydrated, and taking care of your skin can help you manage your symptoms.

• #100 Polycythemia Vera: What’s the Treatment?

  https://www.webmd.com/cancer/polycythemia-vera-treatments

  After your red blood cell level drops, you’ll take one of these prescription drugs to slow the production of new red blood cells in your bone marrow. […] Hydroxyurea is a cancer drug that slows down the growth of new cells in your body. In PV, it lowers the number of red blood cells and platelets, which are cells that help blood clot. […] Your doctor may also consider other treatments such as anagrelide, busulfan (Myleran), imatinib (Gleevec), and ruxolitinib (Jakafi). These medicines help certain types of blood cells work better, so your blood flow improves and is less thick. […] This treatment slows red blood cell production in bone marrow, which thins your blood and helps it flow more easily. […] In addition to your medical plan, use these self-care tips to help you feel better: Exercise daily. Staying active will help keep your blood flowing and prevent clots. […] Drink a lot of water. Extra fluids will help prevent your blood from getting too thick. […] If your concerns start to worry you or get you down, talk to your doctor, a therapist or counselor, or a support group.

• #101 Question: Living with / Treatment Polycythemia Vera (PV) – General chat – Blood Cancer UK Online Community Forum

  https://forum.bloodcancer.org.uk/t/question-living-with-treatment-polycythemia-vera-pv/11246

  If hydroxyurea stops working so well for me in the future then I’ll change to another. […] I hope it feels like you have some kind of treatment plan. […] I am still being treated, so I’m not sure yet what the regularities of my treatment are going to be or if I am going to get medication or not. […] I do find that this is a strange cancer to have as it cannot be seen and once friends and family know you have it and get used to it and see you getting on with life they forget you can get tired and need help. […] I think having a cancer that no one understands or have heard of is hard on everyone the person with it and family and friends. […] I really empathise with how you describe having such a rare cancer versus better known types. […] I know your post was from a couple of months ago now – I’m new to the forum, but already feel a little less alone in this newfound world of living with Polycythaemia vera (PV).

• #102 Question: Living with / Treatment Polycythemia Vera (PV) – General chat – Blood Cancer UK Online Community Forum

  https://forum.bloodcancer.org.uk/t/question-living-with-treatment-polycythemia-vera-pv/11246

  If hydroxyurea stops working so well for me in the future then I’ll change to another. […] I hope it feels like you have some kind of treatment plan. […] I am still being treated, so I’m not sure yet what the regularities of my treatment are going to be or if I am going to get medication or not. […] I do find that this is a strange cancer to have as it cannot be seen and once friends and family know you have it and get used to it and see you getting on with life they forget you can get tired and need help. […] I think having a cancer that no one understands or have heard of is hard on everyone the person with it and family and friends. […] I really empathise with how you describe having such a rare cancer versus better known types. […] I know your post was from a couple of months ago now – I’m new to the forum, but already feel a little less alone in this newfound world of living with Polycythaemia vera (PV).

• #103 Getting Closer to Disease Modification in Polycythemia Vera – Conquer: the journey informed

  https://conquer-magazine.com/issues/2025/vol-11-no-1-february-2025/getting-closer-to-disease-modification-in-polycythemia-vera

  Polycythemia vera is a chronic, incurable disease of the hematopoietic stem cells, the primary cells that can develop into different types of blood cells and are responsible for the production of blood cells during a humans entire life. […] Most affected patients can live a relatively normal and long life. […] Despite the relatively slow progression of the disease course in most patients, the disease possesses its challenges and risks, including a lifetime risk of developing thrombosis (blood clots); the evolution into myelofibrosis, a chronic type of leukemia; or development into acute leukemia. […] Both blood clots and leukemia are consequences that can shorten life expectancy significantly. […] Notwithstanding the rapid advances in therapeutic development, the identification of patients needing therapy and the definition of relevant treatment goals remain challenging.

• #104 Getting Closer to Disease Modification in Polycythemia Vera – Conquer: the journey informed

  https://conquer-magazine.com/issues/2025/vol-11-no-1-february-2025/getting-closer-to-disease-modification-in-polycythemia-vera

  Ultimately, the low-risk patients bear significantly higher rates of all-cause mortality (death from all reasons) and vascular complications, often suffer with uncontrolled symptoms, and eventually face disease progression; the last 2 issues are not addressed by phlebotomies at all. […] Patients with high-risk disease require cytoreductive therapy (medications given to reduce blood cell counts) to further lessen their thrombosis risks. […] An oral chemotherapeutic agent, hydroxyurea, has been used for initial cytoreductive therapy for years, despite its lack of official approval by the FDA. […] The latest interferon form, ropeginterferon alfa-2b, was approved by the FDA in November 2021 after a large phase 3 randomized study confirmed its benefit over hydroxyurea in high-risk polycythemia vera patients.

• #105 Getting Closer to Disease Modification in Polycythemia Vera – Conquer: the journey informed

  https://conquer-magazine.com/issues/2025/vol-11-no-1-february-2025/getting-closer-to-disease-modification-in-polycythemia-vera

  Ultimately, the low-risk patients bear significantly higher rates of all-cause mortality (death from all reasons) and vascular complications, often suffer with uncontrolled symptoms, and eventually face disease progression; the last 2 issues are not addressed by phlebotomies at all. […] Patients with high-risk disease require cytoreductive therapy (medications given to reduce blood cell counts) to further lessen their thrombosis risks. […] An oral chemotherapeutic agent, hydroxyurea, has been used for initial cytoreductive therapy for years, despite its lack of official approval by the FDA. […] The latest interferon form, ropeginterferon alfa-2b, was approved by the FDA in November 2021 after a large phase 3 randomized study confirmed its benefit over hydroxyurea in high-risk polycythemia vera patients.

• #106 Polycythemia Vera | Dr. Srdan Verstovsek – The Patient Story

  https://thepatientstory.com/mpn-specialist/polycythemia-vera-april2022/

  With the phlebotomy, you eliminate iron from the body. The red color is in part of the item may have symptoms from the procedure. Symptoms from iron deficiency. […] Rusfertide, in this case, may come as a choice because it cuts the iron supply to the bone marrow. That’s what it does. Very simple. It stores it in the liver or spleen and other parts of the organ of the body of the patients—no iron for the making of red blood cells. […] It’s quite amazing, actually, the new way of looking at the biology of the disease to cut the supply of the iron to the bone marrow biologically, physiologically, if you like in a body of the patients. […] You can say, three or four are too many. We want patients not to have a need for phlebotomy at all, just to maintain the low number of red blood cells all the time decrease that blood clotting risk as much as you can.

• #107 Getting Closer to Disease Modification in Polycythemia Vera – Conquer: the journey informed

  https://conquer-magazine.com/issues/2025/vol-11-no-1-february-2025/getting-closer-to-disease-modification-in-polycythemia-vera

  Control of blood counts without a need for phlebotomies, improvement of symptoms, and a decline of JAK2 burden from pretreatment were achieved in the majority of patients, who also experienced fewer cardiovascular complications and less progression to myelofibrosis or death (the final disease-modification goal). […] Normalization of blood counts, alleviation of symptoms, and prevention of disease-related complications should remain the cornerstones of polycythemia vera treatment, along with an individualized approach that will offer the best possible disease control for everyone.

• #108 Polycythemia Vera | Dr. Srdan Verstovsek – The Patient Story

  https://thepatientstory.com/mpn-specialist/polycythemia-vera-april2022/

  In fact, just a little bit at the site of injection in some patients, but nobody really stops because it goes away. […] Two-thirds of the patients are just to be at high risk for blood clotting, and phlebotomy alone is not good enough. So you give them chemotherapy by mouth. That’s hydroxyurea or injection under the skin, which is an interferon, a biological product. […] It can be given as a first-line, which would be my preference is the biological agents. It can be given after hydroxyurea as a second line and it works the same way. […] We don’t really know what to do out of it, but it’s very instructive that, yeah, there is a therapy that possibly can aim forward to what you ask for myelofibrosis. […] So these are known not as common. The dropout, meaning, how many people stop the therapy with peginterferon due to side effects, over five years of observation in this study that I described is very low – 10 percent, so it’s not very common.

• #109 Polycythemia Vera – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK557660/

  Polycythemia vera is a myeloproliferative disorder associated with a Janus kinase-2 (JAK2) mutation that causes the neoplastic proliferation of the hematopoietic progenitor cells. […] This activity reviews the evaluation and treatment of polycythemia vera and highlights the role of the interprofessional team in improving care for patients with this condition. […] The role of the interprofessional team to achieve correct diagnosis and management to improve outcomes in patients with polycythemia vera is crucial. This interprofessional team is comprised of clinicians, specialists, mid-level practitioners, nurses, and pharmacists, all working collaboratively and exercising open communication to achieve optimal patient results. […] It is, therefore, important to have frequent follow up with a hematologist for close monitoring and treatment to lower these risks. Treatment options include phlebotomy, daily aspirin, and certain medications to suppress the bone marrow.

• #110 Polycythemia Vera: What It Is, Symptoms & Treatment

  https://my.clevelandclinic.org/health/diseases/17742-polycythemia-vera

  Polycythemia vera is a chronic condition with no cure, but medical care can help you manage symptoms and the risk of complications. […] The most common treatment for PV is to have regular blood withdrawals. Its the same procedure you would have to donate blood. A healthcare technician inserts a needle into a vein in your arm and withdraws a small amount of blood usually a pint, but it may vary depending on your condition. This reduces your overall blood volume and your number of excess blood cells. […] If youre living with polycythemia vera, its important to keep in touch with your healthcare provider so they can keep track of how your condition is progressing. Let them know how youre responding to treatment and if youre experiencing any side effects. You may continue living a long time without severe symptoms.

• #111 Treating Polycythemia Vera: What to Expect

  https://resources.healthgrades.com/right-care/cancer/treating-polycythemia-vera-what-to-expect

  Medications – For longer-term management, your doctor may recommend certain drugs to inhibit the production of red cells by your bone marrow. […] Although polycythemia vera is a chronic, incurable disease, it is important to note that you can expect to live an active lifestyle by following your treatment plan and obtaining ongoing medical care. You should take all medications as recommended and follow up with your doctor regularly to avoid complications.

• #112 Assessment and Management of Patients with Polycythemia Vera – Oncology Nurse Advisor

  https://www.oncologynurseadvisor.com/news/assessment-and-management-of-pts-with-pv/

  Oncology nurses have a key role in monitoring disease status of patients with polycythemia vera (PV), and can provide individualized approaches to help alleviate symptom burden for these patients, according to a review article published in the Clinical Journal of Oncology Nursing. […] Because PV may progress slowly, nurses need to report abnormally elevated hemoglobin, hematocrit, and platelet levels, even if the patient appears asymptomatic, because complications may be avoided with early diagnosis and treatment, noted Jill Brennan-Cook, DNP, who authored the review. […] Dr Brennan-Cook recommended following the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Myeloproliferative Neoplasms to facilitate standardized follow-up for patients with PV. […] Oncology nurses are well suited to assess for symptom burden and provide support with educational interventions to patients [with PV] and their families, concluded Dr Brennan-Cook.

Zobacz więcej